{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lurbinectedin&page=2", "query": { "intervention": "Lurbinectedin", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lurbinectedin&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-26T20:15:06.982Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05099666", "title": "Lurbinectedin + Doxorubicin In Leiomyosarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Soft-tissue Sarcoma", "Metastatic Soft-tissue Sarcoma", "Advanced Leiomyosarcoma", "Leiomyosarcoma Metastatic" ], "interventions": [ { "name": "Lurbinectedin", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2022-02-04", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-26T20:15:06.982Z", "location_count": 6, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Boston, Massachusetts + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05099666" }, { "nct_id": "NCT04894591", "title": "To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Extensive-stage Small-cell Lung Cancer" ], "interventions": [ { "name": "Zepzelca", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 272, "start_date": "2021-06-28", "completion_date": "2025-06-04", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-09-26T20:15:06.982Z", "location_count": 32, "location_summary": "Huntsville, Alabama • Norwich, Connecticut • Brooksville, Florida + 29 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Brooksville", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" }, { "city": "Normal", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04894591" }, { "nct_id": "NCT05876715", "title": "LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Soft-tissue Sarcoma" ], "interventions": [ { "name": "Lurbinectedin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ERLINDA M GORDON", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 40, "start_date": "2023-06-07", "completion_date": "2026-09-30", "has_results": false, "last_update_posted_date": "2024-07-05", "last_synced_at": "2026-09-26T20:15:06.982Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05876715" }, { "nct_id": "NCT06228066", "title": "Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Carcinoma of the Bladder", "High Grade Neuroendocrine Tumors of the Urinary Tract" ], "interventions": [ { "name": "Lurbinectedin", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 45, "start_date": "2024-06-13", "completion_date": "2028-09-01", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-09-26T20:15:06.982Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06228066" }, { "nct_id": "NCT07153055", "title": "Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Cancer ( SCLC )", "Transformed Small Cell Lung Cancer" ], "interventions": [ { "name": "Lurbinectedin", "type": "DRUG" }, { "name": "Osimertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Misty Shields", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2026-08", "completion_date": "2029-10", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-09-26T20:15:06.982Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07153055" }, { "nct_id": "NCT06681220", "title": "Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed Small Cell Lung Cancer", "Recurrent Small Cell Lung Cancer" ], "interventions": [ { "name": "Stenoparib/Temozolomide", "type": "COMBINATION_PRODUCT" }, { "name": "Lurbinectedin", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 166, "start_date": "2026-02-23", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-09-26T20:15:06.982Z", "location_count": 11, "location_summary": "Palo Alto, California • Chicago, Illinois • Indianapolis, Indiana + 8 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06681220" }, { "nct_id": "NCT05578326", "title": "Study of Trilaciclib and Lurbinectidin", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer", "Small-cell Lung Cancer" ], "interventions": [ { "name": "Trilaciclib", "type": "DRUG" }, { "name": "Lurbinectedin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2022-10-12", "completion_date": "2028-12-25", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-09-26T20:15:06.982Z", "location_count": 2, "location_summary": "Lebanon, New Hampshire • Chapel Hill, North Carolina", "locations": [ { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05578326" }, { "nct_id": "NCT01951157", "title": "A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Lurbinectedin (PM01183)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PharmaMar", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 69, "start_date": "2013-09-11", "completion_date": "2016-11", "has_results": true, "last_update_posted_date": "2019-09-24", "last_synced_at": "2026-09-26T20:15:06.982Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01951157" }, { "nct_id": "NCT05042934", "title": "Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Ewing Sarcoma", "Recurrent Ewing Sarcoma" ], "interventions": [ { "name": "Fine-Needle Aspiration", "type": "PROCEDURE" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Lurbinectedin", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 0, "start_date": "2021-09-15", "completion_date": "2022-08-30", "has_results": false, "last_update_posted_date": "2022-02-10", "last_synced_at": "2026-09-26T20:15:06.982Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05042934" }, { "nct_id": "NCT02566993", "title": "Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Small-cell Lung Cancer" ], "interventions": [ { "name": "Lurbinectedin (PM01183)", "type": "DRUG" }, { "name": "Doxorubicin (DOX)", "type": "DRUG" }, { "name": "Cyclophosphamide (CTX)", "type": "DRUG" }, { "name": "Vincristine (VCR)", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PharmaMar", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 613, "start_date": "2016-08-30", "completion_date": "2020-02-24", "has_results": true, "last_update_posted_date": "2021-10-28", "last_synced_at": "2026-09-26T20:15:06.982Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Fullerton, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Whittier", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02566993" } ] }